LQDA · NASDAQ · Medical - Pharmaceuticals

Liquidia (LQDA)

Commercializes inhaled treprostinil therapies for pulmonary hypertension and develops twice-daily L606.

$68.64
After hours0.00 (0.00%)
At close$68.64(+3.33%)
  1. Will LQDA's Differentiated PAH Approach Drive Growth?

    Zacks Investment ResearchOther